Acknowledgements This work was supported by the following grants: National Institutes of Health grant NCI R01CA253329 (L.M.), National Institutes of Health grant NCI U01CA272541 (L.M., J.C.R.), Mark Foundation for Cancer Research (K.E.W, A.H.H., K.I., J.C.R., and L.M.)
Petruzzelli MG, Marzulli L, Margari F, De Giacomo A, Gabellone A, Giannico OV, et al
We determined that a 35 percent applicable percentage was appropriateaccounting for 25 percent lost to adhesion (that is, an 80 mg ( package with maximum extractable dose of 60 mg results in at least 25 percent being discarded) and an additional 10 percent to align with drugs without unique circumstances for patients requiring less than the maximum dose of 60 mg
For Foundayo , orforglipron is being studied as a potential treatment for obstructive sleep apnea, osteoarthritis knee pain, hypertension, peripheral artery disease, and stress urinary incontinence